Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
mTOR inhibitors have demonstrated remarkable anti-tumor activity in experimental models, mainly by reducing cancer cell growth and tumor angiogenesis. Their use in cancer patients as monotherapy has, however, generated only limited benefits, increasing median overall survival by only a few months. L...
Main Authors: | Seraina Faes, Tania Santoro, Nicolas Demartines, Olivier Dormond |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/9/11/152 |
Similar Items
-
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
by: Olivier Dormond, et al.
Published: (2011-05-01) -
Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
by: Alexandre el Hage, et al.
Published: (2021-03-01) -
In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease
by: Alysia Cox, et al.
Published: (2023-08-01) -
A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer’s Disease and Other Neurological Disorders
by: Laura Gianessi, et al.
Published: (2023-12-01) -
AI-Predicted mTOR Inhibitor Reduces Cancer Cell Proliferation and Extends the Lifespan of <i>C. elegans</i>
by: Tinka Vidovic, et al.
Published: (2023-04-01)